Eli Lilly's Obesity Pill Breakthrough Shakes Up $150 Billion Weight-Loss Race
Eli Lilly's Zepbound outperformed Novo Nordisk's Wegovy, boosting Lilly's market lead while a new oral-pill race—potentially reshaped by a recent Lilly announcement—intensifies.